arthritis pain relief, arthritis remedy, pain relief, pain management, arthritis remedies, pain relief product, pain relief options, pain relief products, pain therapy, alternative pain management, arthiritis pain relief, advanced pain therapy, alternative therapy for arthritis, alternative therapy for chronic pain, alternative therapy in arthritis, artharitis pain relief, arthritis pain relief plus, magnets for health, pain management device, pain management products, pain relief magnet, pain relief magnets, pain relief therapies, pain relief therapy

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or for a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of arthritis the treatment. The panel seemed to be in agreement that the statistics indicated a significant pain reduction management in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen for Anibarro, MD, studied five children with asthma with metabisulfite intolerance arthritis confirmed by oral challenge testing. The test was repeated pain after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

All of the active B12 group reporting showed reduction in severity of symptoms ranging from 31% to 70%, while the placebo controls reported either no change or for a worsening of symptoms. Wilcoxon-Rank of .002 for the end-points of sneezing, nasal congestion and runny nose; and p = .005 for IgE reductions. In 1992, the above mentioned data from 1988 on were presented by Dr. O''Connor to the FDA. The FDA panel acknowledged the safety of arthritis the treatment. The panel seemed to be in agreement that the statistics indicated a significant pain reduction management in IgE and that a quantitative drop in symptoms was demonstrated. In 1992, Belen for Anibarro, MD, studied five children with asthma with metabisulfite intolerance arthritis confirmed by oral challenge testing. The test was repeated pain after premedication with 1.5 mg of oral cyanocobalamin. In four of the five patients treated, bronchospasm did not develop in the second metabisulfite challenge.6

©2003 www.alternative-health-treatment.com All rights reserved.